Black Rock Inc. Avenue Therapeutics, Inc. Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.24 - $756.0 $7,003 - $22.1 Million	-29,183 Closed	0 $0
Q2 2022 Aug 12, 2022	SELL	$0.22 - $0.56 $5,653 - $14,389	-25,696 Reduced 46.82%	29,183 $7,000
Q1 2022 May 12, 2022	BUY	$0.22 - $0.96 $1,363 - $5,950	6,198 Added 12.73%	54,879 $27,000
Q4 2021 Feb 10, 2022	BUY	$0.88 - $1.78 $725 - $1,466	824 Added 1.72%	48,681 $44,000
Q3 2021 Nov 09, 2021	SELL	$1.48 - $2.65 $149 - $267	-101 Reduced 0.21%	47,857 $72,000
Q2 2021 Aug 11, 2021	BUY	$2.41 - $7.11 $115,578 - $340,981	47,958 New	47,958 $120,000

Ticker ATXI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,127,720
Market Cap $8.59M
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.